127 related articles for article (PubMed ID: 18661012)
1. High frequency audiometric study in cancer-cured patients treated with cisplatin.
Crepaldi de Almeida EO; Umeoka WG; Viera RC; de Moraes IF
Braz J Otorhinolaryngol; 2008; 74(3):382-90. PubMed ID: 18661012
[TBL] [Abstract][Full Text] [Related]
2. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
3. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.
Weissenstein A; Deuster D; Knief A; Zehnhoff-Dinnesen AA; Schmidt CM
Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):131-6. PubMed ID: 22104469
[TBL] [Abstract][Full Text] [Related]
4. High-frequency audiometric monitoring strategies for early detection of ototoxicity.
Fausti SA; Larson VD; Noffsinger D; Wilson RH; Phillips DS; Fowler CG
Ear Hear; 1994 Jun; 15(3):232-9. PubMed ID: 8076721
[TBL] [Abstract][Full Text] [Related]
5. [The ototoxicity of cisplatin: a clinical study].
Vantrappen G; Rector E; Debruyne F
Acta Otorhinolaryngol Belg; 1990; 44(4):415-21. PubMed ID: 2093285
[TBL] [Abstract][Full Text] [Related]
6. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
[TBL] [Abstract][Full Text] [Related]
7. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives.
van der Hulst RJ; Dreschler WA; Urbanus NA
Ann Otol Rhinol Laryngol; 1988; 97(2 Pt 1):133-7. PubMed ID: 3281541
[TBL] [Abstract][Full Text] [Related]
8. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
9. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
10. Extended high-frequency ototoxicity induced by the first administration of cisplatin.
Sakamoto M; Kaga K; Kamio T
Otolaryngol Head Neck Surg; 2000 Jun; 122(6):828-33. PubMed ID: 10828794
[TBL] [Abstract][Full Text] [Related]
11. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ
Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
[TBL] [Abstract][Full Text] [Related]
13. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
14. [Ototoxicity of cisplatin in children with malignant diseases].
Hadjilaskari P; Fengler R; Hartmann R; Henze G
Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
[TBL] [Abstract][Full Text] [Related]
15. The Relationship Between Cisplatin-related and Age-related Hearing Loss During an Extended Follow-up.
Skalleberg J; Småstuen MC; Oldenburg J; Osnes T; Fosså SD; Bunne M
Laryngoscope; 2020 Sep; 130(9):E515-E521. PubMed ID: 32065408
[TBL] [Abstract][Full Text] [Related]
16. High-frequency monitoring for early detection of cisplatin ototoxicity.
Fausti SA; Henry JA; Schaffer HI; Olson DJ; Frey RH; Bagby GC
Arch Otolaryngol Head Neck Surg; 1993 Jun; 119(6):661-6. PubMed ID: 8499098
[TBL] [Abstract][Full Text] [Related]
17. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
Schmidt CM; Bartholomäus E; Deuster D; Heinecke A; Dinnesen AG
HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215
[TBL] [Abstract][Full Text] [Related]
18. The role of high-frequency audiometry in early detection of ototoxicity.
Dreschler WA; vd Hulst RJ; Tange RA; Urbanus NA
Audiology; 1985; 24(6):387-95. PubMed ID: 4084111
[TBL] [Abstract][Full Text] [Related]
19. Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor.
Polski B; Sosnowska-Sienkiewicz P; Szydłowski J; Januszkiewicz-Lewandowska D
Audiol Neurootol; 2023; 28(1):32-42. PubMed ID: 36191558
[TBL] [Abstract][Full Text] [Related]
20. Audiological profile of patients treated for childhood cancer.
Liberman PH; Goffi-Gomez MV; Schultz C; Novaes PE; Lopes LF
Braz J Otorhinolaryngol; 2016; 82(6):623-629. PubMed ID: 27156673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]